Bexarotene
Bexarotene
Definition
A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties. Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)
Also known as 3-methyl TTNEB, 4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid, BEXAROTENE, LGD 1069, LGD-1069, LGD1069, Targretin — per NCIT
Also identified as
- ATC L01XF03 per RXNORM
- NCIT NCIT:C1635 per NCIT
- SCTID 116346006 per RXNORM
- SCTID 387023000 per RXNORM
- UNII A61RXM4375 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Primary cutaneous T-cell non-Hodgkin lymphoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lymphoid system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Skin of body | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.